Australia's most trusted
source of pharma news
Posted 2 August 2022 PM
Sanofi has thrown down a trump card when it comes to getting ahead of its rivals, with the boss boasting it's the "least exposed" to generic competition of all the Big Pharmas right through to 2030.
CEO Paul Hudson said last week that 2023 marks the last patent cliff free fall for the company this decade, when its MS drug Aubagio opens to generic competition in the US. In Australia, the drug has been off patent since 2019.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.